A brief history of the treatment of viral hepatitis C†

Strader, Doris B.; Seeff, Leonard B.

doi:10.1002/cld.1

Cited by 38 publications

(27 citation statements)

References 197 publications

(188 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2011, the first generation of protease inhibitors (BOC and TVR) were approved as the first direct acting antiviral agents (DAAs) to be used as triple combination with high efficacy reported from clinical trials . Despite gains in the efficacy of these regimens with increasingly better SVR rates, the side effect profile associated with interferon, ribavirin and first‐generation DAAs caused debilitating symptoms and adversely affected patient‐reported outcomes (Table ) …”

Section: Application Of Pro Assessment In Ch‐cmentioning

confidence: 99%

Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens

Younossi

Henry

2015

Aliment Pharmacol Ther

163

189

View full text Add to dashboard Cite

Summary Background Treatment for chronic hepatitis C (CH‐C) is rapidly changing and moving away from an interferon and ribavirin‐based therapy to interferon‐free ribavirin‐free all oral regimens. These regimens are simpler and shorter to administer with very high efficacy rates and better side effect profiles. As advances in the treatment of CH‐C occur, it is imperative to capture both clinical outcomes (efficacy and safety) as well as patient‐reported outcomes (PROs). In fact, PROs assesses and quantifies the impact of these regimens on patient experience. PROs assess patients' health‐related quality of life (HRQOL) especially in the realms of fatigue and neuropsychiatric issues such as depression which can affect treatment adherence and work productivity. Aim To review the literature related to PRO's in HCV patients and summarise the impact of CH‐C and its treatment on PROs. Methods Databases Ovid MEDLINE and PubMed were searched from 1990 to October 2014 using a combination of MEsh, thesaurus terms and relevant text words: hepatitis C, CH‐C, treatment, quality of life, health‐related quality of life, fatigue, work productivity, adherence, patient‐reported outcomes, direct acting anti‐viral agents and second generation direct acting anti‐viral agents. Each manuscript was assessed for pertinence to the issue of PROs in CH‐C as well as the quality of study design and publications. Results From the literature, it is evident that CH‐C patients have baseline PRO impairment. Furthermore, treatment with interferon with or without ribavirin and first generation DAAs causes additional PRO burden which can negatively impact treatment adherence and indirectly, treatment efficacy and work productivity. The new treatment regimens with interferon‐ and ribavirin‐free regimens not only have very high efficacy, but also result in the improvement of PRO scores as early as 2 weeks into treatment as well as possibly better adherence to treatment regimens. Conclusions CH‐C and its treatment have been associated with patient‐reported outcome impairment. The new IF‐free and RBV‐free regimens are associated with high efficacy and substantial improvement of patient‐reported outcomes in clinical trial setting. Although very encouraging, more data are needed to assess patient‐reported outcomes, adherence and work productivity of CH‐C patients in the real world setting of clinical practice.

show abstract

Section: Application Of Pro Assessment In Ch‐cmentioning

confidence: 99%

Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens

Younossi

Henry

2015

Aliment Pharmacol Ther

163

189

View full text Add to dashboard Cite

show abstract

“…SVR of barely 6% was achieved initially with recombinant IFN‐alpha (monotherapy 3 times weekly for 24 weeks), initially used for non A, non B hepatitis; prolonging treatment duration to 48 weeks increased SVR rates to approximately 16% . SVR rates rose to approximately 34% after 24 weeks of treatment following the combination of IFN to ribavirin (RBV) and to approximately 42% after 48 weeks .…”

Section: Interferon‐based Therapiesmentioning

confidence: 99%

“…38,50 SVR of barely 6% was achieved initially with recombinant IFN-alpha (monotherapy 3 times weekly for 24 weeks), initially used for non A, non B hepatitis; prolonging treatment duration to 48 weeks increased SVR rates to approximately 16%. 51 SVR rates rose to approximately 34% after 24 weeks of treatment following the combination of IFN to ribavirin (RBV) and to approximately 42% after 48 weeks. 52,53 Long-acting pegylated IFN (PEG) on monotherapy for 48 weeks induced an SVR rate of approximately 39% and when PEG was added to RBV for 48 weeks, this rate increased to approximately 54%-56%.…”

Section: Interferon-based Therapiesmentioning

confidence: 99%

Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies

Renau

Berenguer

2018

Hemodialysis International

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is an infection that affects over 71 million people worldwide that primarily leads to significant morbidity and mortality through its predisposition to liver fibrosis, cirrhosis, and liver cancer. In addition, extrahepatic manifestations, such as mixed cryoglobulinaemia-associated vasculitis including renal disease, or type II diabetes are frequently encountered in chronically infected individuals. HCV treatment aims to permanently eradicate the virus in order to prevent both liver and extra-hepatic manifestations. Over two decades after the HCV discovery, treatments have evolved from nonspecific immune modulating therapies based on interferon to specific drug combinations, targeting viral proteins. In the present review, we give an overview of HCV infection with a special emphasis on the history of the treatment of viral hepatitis C and the substantial improvement in efficacy and tolerability profile with the recent development of new direct-acting antiviral therapies.

show abstract

“…Accordingly, cirrhosis-, liver disease-, and hepatic cancer-related deaths have increased and remain a leading cause of death worldwide. IFN-based therapies were being explored to treat patients with viral hepatitis prior to the identification of HCV as the causative agent of NANBH (32), and they remained an integral part of the standard of care until the 2010s, especially in combination with ribavirin (RBV) (33). While this course of treatment was able to induce a sustained virologic response rate in approximately 42% of patients after 48 weeks of treatment, the side effects, including fatigue, flu-like symptoms, headache, insomnia, and hematological abnormalities, such as anemia and neutropenia, caused many patients to abandon treatment (34).…”

Section: Searching For a Better Curementioning

confidence: 99%

Ralf Bartenschlager, Charles Rice, and Michael Sofia are honored with the 2016 Lasker~DeBakey Clinical Medical Research Award

Williams¹

2016

Journal of Clinical Investigation

View full text Add to dashboard Cite

A brief history of the treatment of viral hepatitis C†

Cited by 38 publications

References 197 publications

Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens

Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens

Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies

Ralf Bartenschlager, Charles Rice, and Michael Sofia are honored with the 2016 Lasker~DeBakey Clinical Medical Research Award

Contact Info

Product

Resources

About